Skip to main content
Top
Published in: Annals of Surgical Oncology 5/2023

13-01-2023 | Metastasis | Endocrine Tumors

Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status

Authors: Hyunju Park, MD, Jung Heo, MD, Chang-Seok Ki, PhD, Jung Hee Shin, PhD, Young Lyun Oh, PhD, Young Ik Son, PhD, Jee Soo Kim, PhD, Sun Wook Kim, PhD, Jae Hoon Chung, PhD, Tae Yong Kim, PhD, Tae Hyuk Kim, MD, PhD, Jung-Han Kim, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2023

Login to get access

Abstract

Background

A stepwise surgical approach with hemithyroidectomy and completion thyroidectomy was used to achieve definite characterization of follicular thyroid carcinoma (FTC). Choosing appropriate candidates for completion thyroidectomy has been controversial.

Objective

The aim of this study was to clarify the selection criteria for completion thyroidectomy using telomerase reverse transcriptase (TERT) promoter mutation.

Methods

A total of 87 FTC patients who had information about TERT promoter mutation from August 1995 to November 2020 were investigated. The cumulative risk of initial distant metastasis, disease recurrence, and cancer-specific death according to primary tumor size in each of the World Health Organization (WHO) 2017 classifications were calculated.

Results

Of the 87 patients, 8 (9.2%) had initial distant metastasis and 15 (17.2%) had persistent disease or developed structural recurrence. The threshold diameter for initial distant metastasis, disease recurrence, and cancer-specific death was 2 cm in minimally invasive FTC (MI-FTC) with mutant TERT (M-TERT) and in encapsulated angioinvasive FTC (EA-FTC) with M-TERT, while that in MI-FTC with wild-type TERT (WT-TERT) and EA-FTC with WT-TERT was 4 cm. The cumulative risk of initial distant metastasis, disease recurrence, and cancer-specific death according to primary tumor size in each WHO 2017 classification was significantly different only in patients with WT-TERT (p = 0.001, p = 0.019, and p = 0.005, respectively).

Conclusions

The data suggest 2 cm as a critical threshold diameter for performance of completion thyroidectomy in MI-FTC with M-TERT and EA-FTC with M-TERT. TERT promoter mutational status can help select candidates for completion thyroidectomy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sobrinho-Simoes M, Eloy C, Magalhaes J, Lobo C, Amaro T. Follicular thyroid carcinoma. Mod Pathol. 2011;24(Suppl 2):S10–8.CrossRefPubMed Sobrinho-Simoes M, Eloy C, Magalhaes J, Lobo C, Amaro T. Follicular thyroid carcinoma. Mod Pathol. 2011;24(Suppl 2):S10–8.CrossRefPubMed
2.
go back to reference LiVolsi VA, Baloch ZW. Follicular neoplasms of the thyroid: view, biases, and experiences. Adv Anat Pathol. 2004;11(6):279–87.CrossRefPubMed LiVolsi VA, Baloch ZW. Follicular neoplasms of the thyroid: view, biases, and experiences. Adv Anat Pathol. 2004;11(6):279–87.CrossRefPubMed
4.
go back to reference Staubitz JI, Musholt PB, Musholt TJ. The surgical dilemma of primary surgery for follicular thyroid neoplasms. Best Pract Res Clin Endocrinol Metab. 2019;33(4):101292.CrossRefPubMed Staubitz JI, Musholt PB, Musholt TJ. The surgical dilemma of primary surgery for follicular thyroid neoplasms. Best Pract Res Clin Endocrinol Metab. 2019;33(4):101292.CrossRefPubMed
5.
go back to reference Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral
6.
go back to reference Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144(6):1070–7 (discussion 1077-8).CrossRefPubMed Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144(6):1070–7 (discussion 1077-8).CrossRefPubMed
7.
go back to reference Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447–63.CrossRefPubMed Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447–63.CrossRefPubMed
8.
go back to reference Matsuzu K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38(1):68–79.CrossRefPubMed Matsuzu K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38(1):68–79.CrossRefPubMed
9.
go back to reference Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246(3):375–81 (discussion 381-4).CrossRefPubMedPubMedCentral Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246(3):375–81 (discussion 381-4).CrossRefPubMedPubMedCentral
10.
go back to reference Grant CS, Hay ID, Gough IR, Bergstralh EJ, Goellner JR, McConahey WM. Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery. 1988;104(6):954–62.PubMed Grant CS, Hay ID, Gough IR, Bergstralh EJ, Goellner JR, McConahey WM. Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery. 1988;104(6):954–62.PubMed
11.
go back to reference Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery. 1998;124(6):958–64 (discussion 964-6).CrossRefPubMed Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery. 1998;124(6):958–64 (discussion 964-6).CrossRefPubMed
12.
go back to reference O’Neill CJ, Vaughan L, Learoyd DL, Sidhu SB, Delbridge LW, Sywak MS. Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion. Eur J Surg Oncol. 2011;37(2):181–5.CrossRefPubMed O’Neill CJ, Vaughan L, Learoyd DL, Sidhu SB, Delbridge LW, Sywak MS. Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion. Eur J Surg Oncol. 2011;37(2):181–5.CrossRefPubMed
13.
go back to reference Kim HJ, Sung JY, Oh YL, et al. Association of vascular invasion with increased mortality in patients with minimally invasive follicular thyroid carcinoma but not widely invasive follicular thyroid carcinoma. Head Neck. 2014;36(12):1695–700.CrossRefPubMed Kim HJ, Sung JY, Oh YL, et al. Association of vascular invasion with increased mortality in patients with minimally invasive follicular thyroid carcinoma but not widely invasive follicular thyroid carcinoma. Head Neck. 2014;36(12):1695–700.CrossRefPubMed
14.
go back to reference Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs. WHO Classification of Tumours. 4th ed. Lyon: International Agency for Research on Cancer; 2017. Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs. WHO Classification of Tumours. 4th ed. Lyon: International Agency for Research on Cancer; 2017.
15.
go back to reference Xu B, Wang L, Tuttle RM, Ganly I, Ghossein R. Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 276 cases. Hum Pathol. 2015;46(12):1789–98.CrossRefPubMedPubMedCentral Xu B, Wang L, Tuttle RM, Ganly I, Ghossein R. Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 276 cases. Hum Pathol. 2015;46(12):1789–98.CrossRefPubMedPubMedCentral
16.
go back to reference Ito Y, Hirokawa M, Masuoka H, et al. Prognostic factors of minimally invasive follicular thyroid carcinoma: extensive vascular invasion significantly affects patient prognosis. Endocr J. 2013;60(5):637–42.CrossRefPubMed Ito Y, Hirokawa M, Masuoka H, et al. Prognostic factors of minimally invasive follicular thyroid carcinoma: extensive vascular invasion significantly affects patient prognosis. Endocr J. 2013;60(5):637–42.CrossRefPubMed
17.
go back to reference Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98(9):E1562–6.CrossRefPubMedPubMedCentral Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98(9):E1562–6.CrossRefPubMedPubMedCentral
18.
19.
go back to reference Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99(5):E754–65.CrossRefPubMedPubMedCentral Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99(5):E754–65.CrossRefPubMedPubMedCentral
20.
go back to reference Kim TH, Kim YE, Ahn S, et al. TERT promoter mutations and long-term survival in patients with thyroid cancer. Endocr Relat Cancer. 2016;23(10):813–23.CrossRefPubMed Kim TH, Kim YE, Ahn S, et al. TERT promoter mutations and long-term survival in patients with thyroid cancer. Endocr Relat Cancer. 2016;23(10):813–23.CrossRefPubMed
21.
go back to reference Park J, Lee S, Kim K, et al. TERT Promoter Mutations and the 8th Edition TNM Classification in Predicting the Survival of Thyroid Cancer Patients. Cancers (Basel). 2021;13(4):648. Park J, Lee S, Kim K, et al. TERT Promoter Mutations and the 8th Edition TNM Classification in Predicting the Survival of Thyroid Cancer Patients. Cancers (Basel). 2021;13(4):648.
22.
go back to reference Park H, Shin HC, Yang H, et al. Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations. Mod Pathol. 2022;35(2):186–92.CrossRefPubMed Park H, Shin HC, Yang H, et al. Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations. Mod Pathol. 2022;35(2):186–92.CrossRefPubMed
23.
go back to reference Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med. 1996;156(19):2165–72.CrossRefPubMed Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med. 1996;156(19):2165–72.CrossRefPubMed
24.
go back to reference Yi KH, Park YJ, Koong SS, et al. Revised Korean thyroid association management guidelines for patients with thyroid nodules and thyroid cancer. Int J Thyroidol. 2010;3(2):65–96. Yi KH, Park YJ, Koong SS, et al. Revised Korean thyroid association management guidelines for patients with thyroid nodules and thyroid cancer. Int J Thyroidol. 2010;3(2):65–96.
25.
go back to reference Yi KH, Lee EK, Kang HC, et al. 2016 Revised Korean thyroid association management guidelines for patients with thyroid nodules and thyroid cancer. Int J Thyroidol. 2016;9(2):59–126.CrossRef Yi KH, Lee EK, Kang HC, et al. 2016 Revised Korean thyroid association management guidelines for patients with thyroid nodules and thyroid cancer. Int J Thyroidol. 2016;9(2):59–126.CrossRef
26.
go back to reference Sohn SY, Park WY, Shin HT, et al. Highly concordant key genetic alterations in primary tumors and matched distant metastases in differentiated thyroid cancer. Thyroid. 2016;26(5):672–82.CrossRefPubMed Sohn SY, Park WY, Shin HT, et al. Highly concordant key genetic alterations in primary tumors and matched distant metastases in differentiated thyroid cancer. Thyroid. 2016;26(5):672–82.CrossRefPubMed
27.
go back to reference Hennekens CH, Buring JE. Epidemiology in Medicine. Boston/Toronto: Little Brown and Company; 1987. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston/Toronto: Little Brown and Company; 1987.
28.
go back to reference Dralle H, Musholt TJ, Schabram J, et al. German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg. 2013;398(3):347–75.CrossRefPubMed Dralle H, Musholt TJ, Schabram J, et al. German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg. 2013;398(3):347–75.CrossRefPubMed
29.
go back to reference Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81(Suppl 1):1–122.CrossRefPubMed Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81(Suppl 1):1–122.CrossRefPubMed
30.
go back to reference Dionigi G, Kraimps JL, Schmid KW, et al. Minimally invasive follicular thyroid cancer (MIFTC): a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2014;399(2):165–84.CrossRefPubMed Dionigi G, Kraimps JL, Schmid KW, et al. Minimally invasive follicular thyroid cancer (MIFTC): a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2014;399(2):165–84.CrossRefPubMed
31.
go back to reference Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31(8):1256–64.CrossRefPubMed Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31(8):1256–64.CrossRefPubMed
32.
go back to reference Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? Thyroid. 2017;27(6):751–6.CrossRefPubMedPubMedCentral Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? Thyroid. 2017;27(6):751–6.CrossRefPubMedPubMedCentral
33.
go back to reference Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005;103(11):2269–73.CrossRefPubMed Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005;103(11):2269–73.CrossRefPubMed
34.
go back to reference Yang J, Gong Y, Yan S, Chen H, Qin S, Gong R. Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis. Endocrine. 2020;67(1):44–57.CrossRefPubMed Yang J, Gong Y, Yan S, Chen H, Qin S, Gong R. Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis. Endocrine. 2020;67(1):44–57.CrossRefPubMed
35.
go back to reference Collini P, Sampietro G, Pilotti S. Extensive vascular invasion is a marker of risk of relapse in encapsulated non-Hurthle cell follicular carcinoma of the thyroid gland: a clinicopathological study of 18 consecutive cases from a single institution with a 11-year median follow-up. Histopathology. 2004;44(1):35–9.CrossRefPubMed Collini P, Sampietro G, Pilotti S. Extensive vascular invasion is a marker of risk of relapse in encapsulated non-Hurthle cell follicular carcinoma of the thyroid gland: a clinicopathological study of 18 consecutive cases from a single institution with a 11-year median follow-up. Histopathology. 2004;44(1):35–9.CrossRefPubMed
36.
go back to reference Chow SM, Law SC, Au SK, et al. Differentiated thyroid carcinoma: comparison between papillary and follicular carcinoma in a single institute. Head Neck. 2002;24(7):670–7.CrossRefPubMed Chow SM, Law SC, Au SK, et al. Differentiated thyroid carcinoma: comparison between papillary and follicular carcinoma in a single institute. Head Neck. 2002;24(7):670–7.CrossRefPubMed
37.
go back to reference Yip L, Gooding WE, Nikitski A, et al. Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: a matched case-control study. Cancer. 2021;127(11):1779–87.CrossRefPubMed Yip L, Gooding WE, Nikitski A, et al. Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: a matched case-control study. Cancer. 2021;127(11):1779–87.CrossRefPubMed
Metadata
Title
Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status
Authors
Hyunju Park, MD
Jung Heo, MD
Chang-Seok Ki, PhD
Jung Hee Shin, PhD
Young Lyun Oh, PhD
Young Ik Son, PhD
Jee Soo Kim, PhD
Sun Wook Kim, PhD
Jae Hoon Chung, PhD
Tae Yong Kim, PhD
Tae Hyuk Kim, MD, PhD
Jung-Han Kim, MD, PhD
Publication date
13-01-2023
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-13089-5

Other articles of this Issue 5/2023

Annals of Surgical Oncology 5/2023 Go to the issue